63 related articles for article (PubMed ID: 16445808)
1. Nail Society of India Recommendations for Treatment of Onychomycosis in Special Population Groups.
Mahajan K; Grover C; Relhan V; Tahiliani S; Singal A; Shenoy MM; Jakhar D; Bansal S
Indian Dermatol Online J; 2024; 15(2):196-204. PubMed ID: 38550843
[TBL] [Abstract][Full Text] [Related]
2. [New treatments of onychomycoses].
Baran R
Ann Dermatol Venereol; 1992; 119(3):227-31. PubMed ID: 1318667
[No Abstract] [Full Text] [Related]
3. Onychomycosis and AIDS: treatment with topical ciclopirox olamine.
Dompmartin D; Dompmartin A; Deluol AM; Coulaud JP
Int J Dermatol; 1990 Apr; 29(3):233. PubMed ID: 2139871
[No Abstract] [Full Text] [Related]
4. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
Ulbricht H; Wörz K
Mycoses; 1994; 37 Suppl 1():97-100. PubMed ID: 7854374
[TBL] [Abstract][Full Text] [Related]
5. Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer.
Sardana K; Garg VK; Manchanda V; Rajpal M
Br J Dermatol; 2006 Mar; 154(3):573-5. PubMed ID: 16445808
[No Abstract] [Full Text] [Related]
6. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
Gupta AK; Schouten JR; Lynch LE
Skin Therapy Lett; 2005 Sep; 10(7):1-3. PubMed ID: 16292454
[TBL] [Abstract][Full Text] [Related]
7. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
8. Ciclopirox nail lacquer solution 8% in the 21st century.
Gupta AK; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
[TBL] [Abstract][Full Text] [Related]
9. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
Baran R; Kaoukhov A
J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
[TBL] [Abstract][Full Text] [Related]
10. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Subissi A; Monti D; Togni G; Mailland F
Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
